{
    "clinical_study": {
        "@rank": "18239", 
        "arm_group": [
            {
                "arm_group_label": "Dose Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). Up to 5 dose cohorts of up to 6 patients are planned in the dose escalation phase. The starting dose cohort will receive 250 mg twice daily."
            }, 
            {
                "arm_group_label": "Dose Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). The dose will depend on the toxicity seen in the previous cohort. Dose increments of between 25% and 100% are planned at each point of adjustment. The planned dose in dose cohort 2 if the dose is increased at 100% is 500 mg twice daily"
            }, 
            {
                "arm_group_label": "Dose Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). The dose will depend on the toxicity seen in the previous cohort. Dose increments of between 25% and 100% are planned at each point of adjustment. The planned dose in dose cohort 3 if the dose is increased at 100% is 1g twice daily"
            }, 
            {
                "arm_group_label": "2-OHOA Dose Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). The dose will depend on the toxicity seen in the previous cohort. Dose increments of between 25% and 100% are planned at each point of adjustment. The planned dose in dose cohort 4 if the dose is increased at 100% is 2g twice daily"
            }, 
            {
                "arm_group_label": "2-OHOA Dose Cohort 5", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). The dose will depend on the toxicity seen in the previous cohort. Dose increments of between 25% and 100% are planned at each point of adjustment. The planned dose in dose cohort 5 if the dose is increased at 100% is 4g twice daily"
            }, 
            {
                "arm_group_label": "2-OHOA Dose expansion", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). The MTD from the dose escalation phase will be administered"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1/2A, open label, non-randomized study in patients with advanced solid\n      tumours including malignant glioma"
        }, 
        "brief_title": "A Phase 1/2A Study of Minerval in Adult Patients With Advanced Solid Tumours", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glioma", 
            "Other Solid Tumours"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glioma", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open label, non-randomized study in patients with advanced solid tumours\n      including malignant glioma. The study will be performed in two phases - a dose escalation\n      phase following a standard \"3+3\" design to establish dose-limiting toxicity (DLT) and a safe\n      dose of 2-OHOA followed by two expanded safety cohorts (approximately 10 of whom have\n      malignant glioma and approximately 10 of whom have other advanced solid tumours that are\n      suitable for biopsy) treated at the maximum tolerated dose (MTD). If the MTD is well\n      tolerated in the expanded safety cohorts, that dose becomes the recommended phase 2 dose\n      (RP2D). During each dose cohort, at least one week must elapse between the first and\n      subsequent patients receiving treatment with 2-OHOA. Up to five dose cohorts are\n      anticipated.\n\n      Patients may receive palliative localized radiotherapy, if needed (however, this lesion\n      cannot be a target lesion for evaluation of the treatment response).\n\n      Safety, pharmacokinetics (PK), pharmacodynamics and efficacy will be evaluated during the\n      study at pre-defined timepoints"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Males or females providing written, informed consent\n\n          -  Histologically- or cytologically-confirmed advanced solid malignancy that is\n             refractory to standard-of-care treatment, or for which there is no standard therapy.\n             If this is glioma:Grade III / Grade IV malignant glioma recurring or progressing\n             after first or second line standard-of-care treatment and true progressive disease,\n             confirmed according to the RANO criteria 4.\n\n          -  Life-expectancy of at least 12 weeks\n\n          -  Eastern cooperative oncology group (ECOG) performance status of 0-2\n\n          -  Safety laboratory tests and ECGs within specified limits.\n\n          -  Using adequate contraception, where applicable\n\n          -  Presence of lesions suitable for biopsy (mandatory for non-glioma patients enrolled\n             in the expanded safety cohort and highly desirable for non-glioma patients enrolled\n             in the dose escalation phase)\n\n        Exclusion Criteria\n\n          -  Anti cancer therapy within 4 weeks (6 weeks for mitomycin and nitrosureas and 2 weeks\n             for palliative radiotherapy)\n\n          -  NCI Common terminology criteria for adverse events (CTCAE) >Grade 1 toxicities from\n             prior chemotherapy or radiotherapy that could impact on safety outcome assessment\n\n          -  Recent >Grade 1 intracranial or intratumoural haemorrhage either by CT or MRI scan.\n             Patients with resolving haemorrhage changes, punctuate haemorrhage or haemosiderin\n             may enter the study\n\n          -  Significant or uncontrolled cardiovascular disease, unstable angina or myocardial\n             infarction within the preceding 6 months\n\n          -  Known impairment of GI function that could alter the absorption of study drug\n\n          -  History of uncontrolled hyperlipidemia and/or the need for concurrent lipid lowering\n             therapy\n\n          -  Concurrent severe and/or uncontrolled other medical disease that could compromise\n             participation in the study\n\n          -  Taking warfarin, phenytoin or sulphonylureas (glibenclamide, glimepiride, glipizide,\n             glyburide or nateglanide)\n\n          -  Pregnant or breast feeding Other protocol specific criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792310", 
            "org_study_id": "MIN-001-1203", 
            "secondary_id": "EudraCT 2012-001527-13"
        }, 
        "intervention": {
            "arm_group_label": [
                "Dose Cohort 1", 
                "Dose Cohort 2", 
                "Dose Cohort 3", 
                "2-OHOA Dose Cohort 4", 
                "2-OHOA Dose Cohort 5", 
                "2-OHOA Dose expansion"
            ], 
            "description": "Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another \"general\" discontinuation criterion) is met.\nPatients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.\nIn the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of 2-OHOA may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment \"holidays\" of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances.", 
            "intervention_name": "2-hydroxyoleic acid (2-OHOA/2OHOA)", 
            "intervention_type": "Drug", 
            "other_name": "Minerval\u00ae"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Glioma", 
            "Solid Tumours", 
            "Minerval"
        ], 
        "lastchanged_date": "July 18, 2013", 
        "link": {
            "description": "Lipopharma website", 
            "url": "http://www.lipopharma.com/index.php/en/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Vall D'Hebron Institute of Oncology"
                }, 
                "investigator": {
                    "last_name": "Dr Jordi Rodon", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland"
                    }, 
                    "name": "University Hospital"
                }, 
                "investigator": {
                    "last_name": "Dr Roger Stupp", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle", 
                        "country": "United Kingdom", 
                        "state": "Newcastle upon Tyne", 
                        "zip": "NE7 7DN"
                    }, 
                    "name": "Sir Bobby Robson Cancer Trials Research Centre, The Northern Centre for Cancer Care, Freeman Hospital"
                }, 
                "investigator": {
                    "last_name": "Professor Ruth Plummer, BMBCh, MRCP, Cert Me", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM25PT"
                    }, 
                    "name": "The Royal Marsden Hospital Drug Development Unit"
                }, 
                "investigator": {
                    "last_name": "Professor Johann deBono, MB ChB FRCP MSc PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Spain", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minerval\u00ae) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma", 
        "overall_contact": {
            "email": "v.tur@lipopharma.com", 
            "last_name": "Vicen\u00e7 Tur", 
            "phone": "(+34) 971439886"
        }, 
        "overall_contact_backup": {
            "email": "info@lipopharma.com", 
            "last_name": "Servidor"
        }, 
        "overall_official": [
            {
                "affiliation": "The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG", 
                "last_name": "Professor Johann de Bono, MB ChB FRCP MSc PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Northern Institute for Cancer Research, Newcastle", 
                "last_name": "Prof. Ruth Plummer, BMBCh, MRCP, Cert Me", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Vall D\u2019Hebron Institute of Oncology, Barcelona", 
                "last_name": "Dr Jordi Rodon", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Zurich", 
                "last_name": "Dr Roger Stupp", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Spain: Spanish Agency of Medicines", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All adverse events will be recorded including clinically significant physical examinations and vital signs, laboratory safety tests and 12-lead electrocardiograms", 
            "measure": "Number of patients with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "From the first dose of study drug until 30 days after the last dose of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792310"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Full profiles on Day 1 and Day 21 (dose escalation phase only), trough measurements on Day 8, 15 and 21", 
                "measure": "Concentration of 2-OHOA in blood measured by LC-MS/MS", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "description": "Effect on glial fibrillary acidic protein in glioma patients and effect on sphingomyelin and dihydrofolate reductase in patients with other solid tumours", 
                "measure": "Concentration of biomarkers in blood or tumour tissue", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "description": "Measurement by CT or MRI scan. Changes scored according to Response Assessment in Neuro-oncology (RANO) criteria (for glioma patients) or Response evaluation criteria in solid tumours (RECIST v1.1) (for other solid tumour patients).", 
                "measure": "Radiological disease progression", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks"
            }, 
            {
                "measure": "Clinical disease progression", 
                "safety_issue": "No", 
                "time_frame": "126 days (based upon 6 cycles)"
            }
        ], 
        "source": "Lipopharma Therapeutics SL", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Specialized Medical Services (SMS)-Oncology BV", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Royal Marsden NHS Foundation Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Northern Institute for Cancer Research, Newcastle", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Zurich", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Vall D\u2019Hebron Institute of Oncology, Barcelona", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Lipopharma Therapeutics SL", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}